质子抑制剂的心血管兼容性:实践建议
Jamshed Dalal1, Anjan Lal Dutta2, Jagdish Hiremath3
1Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. jamshed.dalal@relianceada.com.
Cardiology and therapy
|November 10, 2023
概括
质子抑制剂 (PPI) 在冠状动脉疾病患者中可能存在心血管风险. 专家建议PPI具有最小的药物相互作用,如rabeprazole,特别是对于那些服用克洛皮多格雷尔或多种药物的人.
科学领域:
- 心脏病学 心脏病学
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 质子抑制剂 (PPI) 广泛用于预防GERD和胃肠道出血.
- 人们担心PPI可能对心血管产生不良影响,特别是在冠状动脉疾病 (CAD) 患者中.
- 管理多药和药物相互作用 (DDI) 在心血管患者护理中至关重要.
研究的目的:
- 在CAD患者中批判性地评估与PPI相关的心血管风险的证据.
- 为选择适当的个人保护剂提供指导,考虑到心血管多药学.
- 强调需要具有有限CYP450抑制的PPI来最大限度地减少DDI.
主要方法:
- 对PPI和心血管影响的现有文献的审查.
- 印度心脏病学和胃肠病学专家的一致会议的记录.
- 通过多轮审查对14个共识陈述的评估.
主要成果:
- 达成共识,对具有最小药物相互作用 (DDI) 的PPI的需求达成共识.
- 对于具有有限的细胞色素P450 (CYP450) 酶抑制的PPI的建议.
- 由于最佳的酸抑制和最小的DDI配置文件,Rabeprazole被确定为合适的选择.
结论:
- 选择PPI应优先考虑最小的DDI,特别是在服用克洛皮多格雷尔或多药剂的患者中.
- 临床医生应致力于就处方低CYP450相互作用潜力的PPI达成共识.
- 拉贝普拉在需要PPI的心血管患者中为联合处方提供了有利的概况.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
490
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
490
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
376
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
376
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
539
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
539


